MSH2 and carcinoma: Concurrent loss of MLH1/PMS2 expression was the most common phenotype of MMR-negative colorectal [20, 22–25] and endometrial [21, 24, 26] carcinoma, followed by concurrent loss of MSH2/MSH6 expression.